HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bath & Body Works CEO

This article was originally published in The Rose Sheet

Executive Summary

Neil Fiske to CEO, joining recently-appointed President Ken Stevens in redefining the specialty retail brand, Limited Brands announces Feb. 10. Fiske will be responsible for raising level and pace of innovation, focusing on new product development and seasonal category planning, brand marketing and sub-brand definition and positioning, firm states. Exec joins B&BW after nearly 14 years with The Boston Consulting Group, where he specialized in consumer goods, retail and brand leadership. He worked for six years exclusively on Limited Brands business while at BCG, playing an "integral" role in Victoria's Secret, Express and B&BW, according to Limited Brands. Fiske and Stevens succeed Beth Pritchard, who announced she would depart B&BW after 12 years at the helm (1"The Rose Sheet" Jan. 20, 2003, p. 3)...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS010964

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel